ClinicalTrials.gg
CompletedNCT04241809Updated Mar 27, 2023

Bioaerosol Sampling in Suspected Pulmonary Tuberculosis

An observational study in Pulmonary Tuberculosis Confirmation by Sputum Microscopy With or Without Culture, sponsored by Desmond Tutu HIV Foundation. Completed at 1 site in South Africa. Open to participants aged 13 Years to 100 Years. Per ClinicalTrials.gov, last updated 2023-03-27.

Sponsored by Desmond Tutu HIV Foundation · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
102
Ages
13 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 78 studies in Tuberculosis, Pulmonary with a site in South Africa — 10 open to participants now, 13 under way, 3 of them phase 3. Tuberculosis, Pulmonary · South Africa.

Enrollment
10th of 11
102 · median 900
Started
2020
with 5 others
Observational
11 of 78
none open now
Registered
43rd of 78
by date

Among the 78 studies in Tuberculosis, Pulmonary with a site in South Africa, this one is the 10th largest by enrollment of the 11 observational ones that give a count, is one of 6 that started in 2020, is one of 11 observational ones, and was the 43rd registered.

Tuberculosis, Pulmonary

320 studies on the registry are indexed under Tuberculosis, Pulmonary; 72 are open to participants now.

Browse Tuberculosis, Pulmonary studies →

Open to participants now

10 of the 78 studies in Tuberculosis, Pulmonary with a site in South Africa are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in South Africa have not opened yet or have stopped. Only those recruiting at a site in South Africa →

Who these studies take

Of the 47 Tuberculosis, Pulmonary studies recruiting now, 22 (47%) set no upper age limit and 21 (45%) stop at 75 or younger; 12 take children under 18; 7 take healthy volunteers.

This study: 13 Years to 100 Years · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 78 studies in Tuberculosis, Pulmonary with a site in South Africa, or all of them as a file.
02

Study summary

Tuberculosis (TB) is transmitted in bioaerosols containing Mycobacterium tuberculosis (Mtb). Mtb-containing bioaerosols are likely related to host infectiousness and central to ongoing TB transmission. No routine diagnostic assay exists to measure Mtb in bioaerosols. Furthermore, published studies of Mtb in bioaerosol samples, have been limited to individuals with sputum-positive pulmonary TB. Currently TB diagnosis is based on clinical symptoms and sputum laboratory findings. However, approximately half of all patients commencing TB treatment are sputum negative resulting in a high proportion of presumptive treatments. We therefore propose to use a sensitive sampling protocol to investigate the prevalence of Mtb-containing bioaerosols in both sputum-positive and sputum-negative TB suspects.

Read the detailed description

Our pragmatic, parallel-group design is aimed at identifying viable Mtb in bioaerosols produced by individuals attending a TB clinic in Cape Town, South Africa. Bioaerosol sampling will be performed on all eligible individuals presenting with symptoms indicative of TB and repeated at 14 days if initially positive for viable Mtb. Participants will be classified into three distinct groups based on the National TB Control Program (NTBCP) criteria: Group A, TB notification with sputum-based laboratory confirmation; Group B, TB notification with empiric diagnosis; and Group C, individuals not notified. Group C individuals with detectable Mtb bioaerosol will be monitored until resolution of clinical and laboratory status. Collection of bioaerosol specimens will be via two consecutive sampling modalities: (1) direct sampling of a specific respiratory manoeuvre; and (2) indirect sampling following passive respiratory activity and environmental sampling. microscopy. Mtb genomes and mycobacterial and host lipids will be detected using droplet digital PCR and mass spectrometry analyses, respectively. The primary objective is to determine the prevalence of Mtb bioaerosols in all TB clinic attendees and in each of the mutually exclusive groups A, B and C. Secondary objectives are to investigate differences in prevalence of Mtb bioaerosol by HIV status, current isoniazid preventive therapy (IPT) use and pre and post initiation of anti-TB chemotherapy.

03

Conditions studied

  • Pulmonary Tuberculosis Confirmation by Sputum Microscopy With or Without Culture
04

Who can participate

Ages eligible
13 Years to 100 Years
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Consecutive patients with respiratory and/or constitutional symptoms suggestive of pulmonary TB who self-present to two TB clinics in high density peri-urban settlements in Cape Town, South Africa will be offered recruitment to the study

Eligibility criteria

Inclusion Criteria:

  • age over 13 years
  • person with suspected TB
  • provision of written, (parental consent and patient assent for those aged under 18yrs)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
102 participants (actual)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • A: Notified TB with sputum laboratory confirmation

    Bioaerosol Sampling: (1) direct sampling of a specific respiratory manoeuvre; and (2) indirect, following passive respiratory activity and environmental sampling. Repeat bioaerosol sampling will be conducted at 14 days.

    Diagnostic Test: Bioaerosol Sampling

  • B: Notified TB without sputum laboratory confirmation

    Bioaerosol Sampling: (1) direct sampling of a specific respiratory manoeuvre; and (2) indirect, following passive respiratory activity and environmental sampling. Repeat bioaerosol sampling will be conducted at 14 days.

    Diagnostic Test: Bioaerosol Sampling

  • C: Not Notified for TB

    Bioaerosol Sampling: (1) direct sampling of a specific respiratory manoeuvre; and (2) indirect, following passive respiratory activity and environmental sampling. Repeat bioaerosol sampling will be conducted at 14 days.

    Diagnostic Test: Bioaerosol Sampling

Interventions

  • Diagnostic testBioaerosol Sampling

    Cyclone collection of exhaled bioaerosol

06

What researchers measure

Primary outcomes

  1. Primary Aim

    The difference in prevalence proportions of Mtb-containing bioaerosol in sputum positive and sputum negative pulmonary TB cases (Groups A \& B)

    Time frame: 12 months

Secondary outcomes

  1. Secondary Aim (1)

    The difference in numbers of viable MTB organisms in bioaerosols per liter of air sampled and per nano-liter of bioaerosol particulate volume collected in both sputum positive and sputum negative pulmonary TB cases (Groups A \& B).

    Time frame: 12 months

Other outcomes

  1. Exploratory Aim (1)

    The prevalence of MTB containing bioaerosols in TB suspects not diagnosed with clinical TB (Group C)

    Time frame: 12 months

  2. Exploratory Aim (2)

    The difference in prevalence and numbers of viable MTB in subjects receiving and not receiving IPT prophylaxis.

    Time frame: 12 months

  3. Exploratory Aim (3)

    The difference in prevalence and numbers of viable MTB in subjects with and without HIV-infection.

    Time frame: 12 months

  4. Exploratory Aim (4)

    The difference in prevalence and numbers of viable MTB in subjects before and after TB therapy.

    Time frame: 12 months

  5. Exploratory Aim (5)

    The difference in numbers of viable MTB in bioaerosol collected by direct and indirect sampling.

    Time frame: 12 months

  6. Exploratory Aim (6)

    The ratio of MTB genomes (ddPCR) to viable MTB organisms (DMN-tre-positive) in MTB containing bioaerosol

    Time frame: 12 months

  7. Exploratory Aim (7)

    Which MTB lipids are present in MTB containing bioaerosol

    Time frame: 12 months

07

Study locations

1 site
  • Aerobiology Research Centre
    Cape Town, Western Cape, South Africa
08

References and documents

Publications

  • Patterson B, Koch A, Gessner S, Dinkele R, Gqada M, Bryden W, Cobelens F, Little F, Warner DF, Wood R. Bioaerosol sampling of patients with suspected pulmonary tuberculosis: a study protocol. BMC Infect Dis. 2020 Aug 8;20(1):587. doi: 10.1186/s12879-020-05278-y. Erratum In: BMC Infect Dis. 2020 Aug 24;20(1):624. doi: 10.1186/s12879-020-05342-7. PubMed 32770954 ↗

Individual participant data

Plan to share: Yes — The outcomes of the analysis in addition to the unprocessed data will be submitted for publication in open-source peer-reviewed journals and presented at international conferences.

Supporting information: Study protocol, Statistical analysis plan

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2020 to primary completion in May 2022, 24 months.

Of 45 observational studies under Tuberculosis, Pulmonary, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 49. This study's 24 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 27, 2019
First posted
Jan 27, 2020
StartActual
May 15, 2020
Primary completionActual
May 27, 2022
CompletionActual
May 27, 2022
Last update
Mar 27, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 27, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04241809
Lead sponsor
Desmond Tutu HIV Foundation
Collaborators
National Institutes of Health (NIH), University of Cape Town, Zeteo Tech Incorporated
Responsible party
Sponsor
First posted
Jan 27, 2020
Start date
May 15, 2020
Primary completion
May 27, 2022
Completion
May 27, 2022
Last update
Mar 27, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion